A Randomized, Double-Blind, Controlled Study of NGX-4010, a Capsaicin 8% Dermal Patch, for the Treatment of Painful HIV-Associated Distal Sensory Polyneuropathy
Authors:
- David B. CliffordDCDavid B. Clifford
- David M. SimpsonDSDavid M. Simpson
- Stephen BrownSBStephen Brown
- Graeme MoyleGMGraeme Moyle
- Bruce J. BrewBBBruce J. Brew
- Brian ConwayBCBrian Conway
- Jeffrey K. TobiasJTJeffrey K. Tobias
- Geertrui F. VanhoveGVGeertrui F. Vanhove
- 1 February 2012
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 59 (2) , 126-133
Abstract
Effective treatment of HIV-associated distal sensory polyneuropathy remains a significant unmet therapeutic need. In this randomized, double-blind, controlled study, patients with pain due to HIV-associated distal sensory polyneuropathy received a single 30-minute or 60-minute application of NGX-4010--a capsaicin 8% patch (n = 332)--or a low-dose capsaicin (0.04%) control patch (n = 162). The primary endpoint was the mean percent change from baseline in Numeric Pain Rating Scale score to weeks 2-12. Secondary endpoints included patient global impression of change at week 12. Pain reduction was not significantly different between the total NGX-4010 group (-29.5%) and the total control group (-24.5%; P = 0.097). Greater pain reduction in the 60-minute (-30.0%) versus the 30-minute control group (-19.1%) prevented intended pooling of the control groups to test individual NGX-4010 treatment groups. No significant pain reduction was observed for the 30-minute NGX-4010 group compared with 30-minute control (-26.2% vs.-19.1%, respectively, P = 0.103). Pain reductions in the 60-minute NGX-4010 and control groups were comparable (-32.8% vs. -30.0%, respectively; P = 0.488). Posthoc nonparametric testing demonstrated significant differences favoring the total (P = 0.044) and 30-minute NGX-4010 groups (P = 0.035). Significantly, more patients in the total and 30-minute NGX-4010 group felt improved on the patient global impression of change versus control (67% vs. 55%, P = 0.011 and 65% vs. 45%, P = 0.006, respectively). Mild to moderate transient application site pain and erythema were the most common adverse events. Although the primary endpoint analyses were not significant, trends toward pain improvement were observed after a single 30-minute NGX-4010 treatment.Keywords
This publication has 31 references indexed in Scilit:
- Continued High Prevalence and Adverse Clinical Impact of Human Immunodeficiency Virus–Associated Sensory Neuropathy in the Era of Combination Antiretroviral TherapyArchives of Neurology, 2010
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- EFNS guidelines on neurostimulation therapy for neuropathic painEuropean Journal of Neurology, 2007
- HIV neuropathy natural history cohort studyNeurology, 2006
- Human Immunodeficiency Virus-Associated Peripheral NeuropathiesMayo Clinic Proceedings, 2006
- HIV-Associated Distal Sensory Polyneuropathy in the Era of Highly Active Antiretroviral TherapyArchives of Neurology, 2004
- HIV-associated sensory neuropathiesAIDS, 2002
- Epidemiology and clinical features of HIV‐1 associated neuropathiesJournal of the Peripheral Nervous System, 2001
- Symptom Prevalence, Characteristics, and Distress in AIDS OutpatientsJournal of Pain and Symptom Management, 1999
- Pain syndromes and etiologies in ambulatory AIDS patientsPain, 1997